vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) to a sell rating in a research report sent to investors on Saturday.

Several other equities research analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 22nd. HC Wainwright reissued a “buy” rating and set a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. Finally, BTIG Research initiated coverage on shares of vTv Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $43.50.

vTv Therapeutics Stock Up 0.2%

NASDAQ:VTVT opened at $37.97 on Friday. The company has a market cap of $149.60 million, a P/E ratio of -11.44 and a beta of 0.50. The firm’s 50 day moving average is $29.02 and its two-hundred day moving average is $21.72. vTv Therapeutics has a fifty-two week low of $13.15 and a fifty-two week high of $38.70.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Trading of vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP increased its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.